The promising AChE and BChE inhibitory capabilities of our synthesised chromium oxide nanoparticles implies that such NPs could be used therapeutically in neurodegenerative illnesses, including Alzheimer’s disease. The gene discussed is BCHE; the disease is early-onset autosomal dominant Alzheimer disease.